Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 9/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551738 | 1.00 | KIF11 (0.36) | KIF11ARSCN8ASLC22A12AKR1C3 | |
| SCHEMBL20551077 | 0.86 | KIF11 (0.46) | KIF11 | |
| SCHEMBL474259 | 0.86 | KIF11 (0.46) | KIF11 | |
| SCHEMBL20551343 | 0.81 | KDR (0.41) | SCN8AAKR1C3AKR1C2 | |
| SCHEMBL1726228 | 0.81 | KDR (0.41) | SCN8AAKR1C3AKR1C2 | |
| SCHEMBL998053 | 0.80 | CES2 (0.42) | AKR1C3AKR1C2 | |
| SCHEMBL27664128 | 0.79 | AKR1C3 (0.39) | KIF11ARSCN8ASLC22A12AKR1C3 | |
| SCHEMBL2338758 | 0.79 | EPHX1 (0.36) | KIF11ARSCN8ASLC22A12AKR1C3 | |
| SCHEMBL7020637 | 0.79 | KMO (0.38) | KIF11ARSCN8ASLC22A12AKR1C3 | |
| SCHEMBL27821736 | 0.79 | KMO (0.33) | KIF11ARSCN8ASLC22A12AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
| EP-2358710-A1 | AKT AND P70 S6 KINASE INHIBITORS | Eli Lilly and Company (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-2265606-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010056563-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009129109-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-1874765-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | Proskelia SAS (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117211-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | PROSKELIA SAS (FR) | 2006-11-09 | — | — | WO | disclosed |